To overcome this challenge, as well as to explore mechanisms for improving current PD-1/PD-L1 immunotherapies, we have developed a novel approach by fusing IFN- α to an anti-PD-L1 antibody to direct IFN-alpha activity specifically to the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.